Pediatric Ondansetron (Ondem) Dosing
For pediatric patients, ondansetron should be dosed at 0.15 mg/kg IV (up to maximum 16 mg) for chemotherapy-induced nausea/vomiting, or 0.1 mg/kg IV (maximum 4 mg) for postoperative nausea/vomiting, with weight-based oral dosing of 2-4 mg depending on the clinical indication.
Weight-Based Dosing by Indication
Chemotherapy-Induced Nausea and Vomiting (CINV)
- Intravenous: 0.15 mg/kg per dose, administered three times (at 0,4, and 8 hours after chemotherapy start) 1
- This dosing was validated in children as young as 6 months up to 48 months 1
- Important caveat: For infants under 4 months, clearance is reduced by 76%, and under 6 months by 53% 2. Close monitoring is essential in this age group, and a reduced dose of 0.1 mg/kg should be considered 2
Postoperative Nausea and Vomiting (PONV)
For prevention:
- Children ≤40 kg: 0.1 mg/kg IV over at least 30 seconds 1
- Children >40 kg: 4 mg IV over at least 30 seconds 1
- Administer immediately before or after anesthesia induction 1
For treatment of established PONV:
- Same dosing as prevention: 0.1 mg/kg (≤40 kg) or 4 mg (>40 kg) IV 1
Oral dosing for PONV (based on research evidence):
- Optimal dose is 0.15 mg/kg orally, which is more effective than 0.075 mg/kg 3
- For strabismus surgery specifically, 75 mcg/kg (0.075 mg/kg) IV is as effective as higher doses 4
Gastroenteritis-Associated Vomiting
Oral dosing (weight-based):
- 8-15 kg: 2 mg orally 5
- >15 kg: 4 mg orally 5
- Single dose administration significantly reduced vomiting and IV rehydration needs 5
Intravenous dosing:
- 0.2 mg/kg IV single dose effectively stops vomiting and reduces IV rehydration requirements 6
Key Clinical Considerations
Age-Related Pharmacokinetics
The most critical factor in very young children is the maturation of ondansetron clearance. Clearance is dramatically reduced in infants under 6 months due to immature hepatic metabolism, with a maturation half-life of approximately 4 months 2. This means:
- 1-month-old: 76% reduction in clearance
- 3-month-old: 53% reduction in clearance
- 6-month-old: 31% reduction in clearance
For infants under 6 months, use 0.1 mg/kg instead of 0.15 mg/kg and monitor closely 2.
Dosing Frequency Considerations
For CINV, recent evidence suggests that divided dosing (0.15 mg/kg every 8 hours) may be superior to single daily dosing (0.3 mg/kg once daily) in children under 7 years for preventing nausea symptoms, though both strategies are equally effective for preventing vomiting 7. For children under 7 years receiving chemotherapy, consider the divided dosing approach.
Maximum Doses
- Single IV dose maximum: 16 mg (though FDA label data shows 4-8 mg is standard for adults) 8
- Daily oral maximum: 16 mg 8
Common Pitfalls to Avoid
Don't underdose in postoperative settings: The 0.1 mg/kg dose for PONV is specifically validated; don't reduce it further 1
Don't use repeat dosing for inadequate PONV control: If a single prophylactic 4 mg IV dose fails in postoperative patients, giving a second 4 mg dose does not provide additional benefit 1
Don't forget age-adjusted dosing in infants: Failure to reduce doses in infants under 6 months risks toxicity due to reduced clearance 2
For gastroenteritis, oral route is effective: Don't default to IV when oral ondansetron (2-4 mg based on weight) works well and reduces need for IV rehydration 5, 9
Multi-dose Regimens for Gastroenteritis
Recent high-quality evidence shows that providing caregivers with take-home ondansetron doses (up to 6 doses over 48 hours) after emergency department discharge significantly reduces moderate-to-severe gastroenteritis compared to placebo 9. This represents an evidence-based strategy for outpatient management.
Safety Profile
Ondansetron is well-tolerated in pediatrics with no significant QTc prolongation observed in dosing studies 7. The most common adverse effects are headache and constipation, with rates similar between ondansetron and placebo groups 1, 7.